ArticleMolecular pharmaceutics2010
Expanding the utility of beta-galactosidase complementation: piece by piece.
Article in Molecular pharmaceutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- A general assay platform to study protein pharmacology using ligand-dependent structural dynamics.Nature communications · 2025Article
- Orthogonal Light-Activated DNA for Patterned Biocomputing within Synthetic Cells.Journal of the American Chemical Society · 2023Article
- Modular Peroxidase-Based Reporters for Detecting Protease Activity and Protein Interactions with Temporal Gating.Journal of the American Chemical Society · 2022Article
- Developing a far-red fluorogenic beta-galactosidase probe for senescent cell imaging and photoablation.RSC advances · 2022Article
- De novo engineering of intracellular condensates using artificial disordered proteins.Nature chemistry · 2020Article
- Directed Evolution of Split APEX2 Peroxidase.ACS chemical biology · 2019Article
- Surveying the landscape of optogenetic methods for detection of protein-protein interactions.Wiley interdisciplinary reviews. Systems biology and medicine · 2018Review
- Synthesis and evaluation of MR probes for targeted-reporter imaging.Chemical science · 2017Article
- Dual Receptor-Targeted Theranostic Nanoparticles for Localized Delivery and Activation of Photodynamic Therapy Drug in Glioblastomas.Molecular pharmaceutics · 2015Article
- Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levels.Bioconjugate chemistry · 2015Article
- A fluorogenic probe for β-galactosidase activity imaging in living cells.Molecular bioSystems · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The ability to image and quantify multiple biomarkers in disease necessitates the development of split reporter fragment platforms. We have divided the beta-galactosidase enzyme into unique, independent polypeptides that are able to reassemble and complement enzymatic activity in bacteria and in mammalian cells. We created two sets of complementing pairs that individually have no enzymatic activity. However, when brought into close geometric proximity, the complementing pairs associated resulting in detectable enzymatic activity. We then constructed a stable ligand complex composed of reporter fragment, linker, and targeting moiety. The targeting moiety, in this case a ligand, allowed cell surface receptor targeting in vitro. Further, we were able to simultaneously visualize two cell surface receptors implicated in cancer development, epidermal growth factor receptor and transferrin receptor, using complementing pairs of the ligand-reporter fragment complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.